Clinical Research Directory

Inclusion Criteria: * Cancer of the uterine cervix suitable for curative treatment with definitive radio-chemotherapy * Biopsy proven showing squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix. * Pelvic MRI. * MRI and Positron emission tomography (PET-CT) of the retroperitoneal space and abdomen at diagnosis is performed. * Stage IIB to IVA according to International Federation of Gynecological and Obstetrics (FIGO) and TNM guidelines. * Planning MRI with the applicator in place for the SBRT boost. * Para-aortic metastatic nodes below L1-L2 are allowed. * Study specific signed patient informed consent. Exclusion Criteria: * Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin. * Small cell neuroendocrine cancer, melanoma and other rare cancers in the cervix. * Metastatic disease above and beyond the retroperitoneal paraaortic L1-L2 interspace. * Previous pelvic or abdominal radiotherapy. * Previous total or partial hysterectomy. * Contra-indications to MRI. * Severe psychiatric condition. * Severe, active co-morbidity.